Frazier Life Sciences Management, L.P. reported 40 positions worth $4.58B for the quarter ended Jun 30, 2026, up 21.3% on the prior quarter. It opened 6 new positions, added to 8, trimmed 2 and exited 2. Its largest holding is Mirum Pharmaceuticals, Inc. at 19.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| PBLS Parabilis Medicines, Inc. | +1.92M | – | $52.57M | 1.15% |
| ACHV Achieve Life Sciences, Inc. | +7.61M | – | $49.72M | 1.09% |
| NAMS NewAmsterdam Pharma Co N.V. | +1.15M | +6.8% | $38.81M | 13.38% |
| ALLO Allogene Therapeutics, Inc. | +18.65M | +491.2% | $38.79M | 1.02% |
| DSGN Design Therapeutics, Inc. | +1.81M | – | $26.19M | 0.572% |
| STTK Shattuck Labs, Inc. | +3.75M | – | $26.03M | 0.568% |
| ASND Ascendis Pharma A/S | +91.8K | +68.9% | $24.49M | 1.31% |
| KLRA Kailera Therapeutics, Inc. | +1.10M | – | $24.23M | 0.529% |
| RLAY Relay Therapeutics, Inc. | +1.02M | – | $19.00M | 0.415% |
| AURA Aura Biosciences, Inc. | +2.00M | +39.2% | $14.20M | 1.1% |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| PBLS Parabilis Medicines, Inc. | +1.92M | $52.57M | 1.15% |
| ACHV Achieve Life Sciences, Inc. | +7.61M | $49.72M | 1.09% |
| DSGN Design Therapeutics, Inc. | +1.81M | $26.19M | 0.572% |
| STTK Shattuck Labs, Inc. | +3.75M | $26.03M | 0.568% |
| KLRA Kailera Therapeutics, Inc. | +1.10M | $24.23M | 0.529% |
| RLAY Relay Therapeutics, Inc. | +1.02M | $19.00M | 0.415% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | MIRM Mirum Pharmaceuticals, Inc. | Healthcare | 7.68M | $899.06M | 19.62% | 0 | 0.0% | Unchanged | 11.86% |
| 2 | NAMS NewAmsterdam Pharma Co N.V. | Healthcare | 18.09M | $613.03M | 13.38% | +1.15M | +6.8% | Added | 14.66% |
| 3 | ERAS Erasca, Inc. | Healthcare | 24.98M | $457.55M | 9.99% | +300.0K | +1.2% | Added | 7.99% |
| 4 | MBX MBX Biosciences, Inc. | Healthcare | 6.65M | $367.19M | 8.01% | 0 | 0.0% | Unchanged | 13.87% |
| 5 | ARQT Arcutis Biotherapeutics, Inc. | Healthcare | 9.87M | $258.91M | 5.65% | 0 | 0.0% | Unchanged | 7.57% |
| 6 | TRVI Trevi Therapeutics, Inc. | Healthcare | 9.94M | $185.37M | 4.05% | -100 | 0.0% | Reduced | 6.35% |
| 7 | KRYS Krystal Biotech, Inc. | Healthcare | 481.3K | $178.89M | 3.9% | 0 | 0.0% | Unchanged | 1.63% |
| 8 | MAZE Maze Therapeutics, Inc. | Healthcare | 5.03M | $150.18M | 3.28% | +465.6K | +10.2% | Added | 8.53% |
| 9 | PHAT Phathom Pharmaceuticals, Inc. | Healthcare | 12.47M | $135.26M | 2.95% | 0 | 0.0% | Unchanged | 14.89% |
| 10 | PVLA Palvella Therapeutics, Inc. | Healthcare | 882.4K | $134.85M | 2.94% | 0 | 0.0% | Unchanged | 6.13% |
| 11 | BBIO BridgeBio Pharma, Inc. | Healthcare | 1.55M | $115.31M | 2.52% | -1.90M | -55.1% | Reduced | 0.79% |
| 12 | IRON Disc Medicine, Inc. | Healthcare | 1.35M | $99.09M | 2.16% | 0 | 0.0% | Unchanged | 3.5% |
| 13 | CYTK Cytokinetics Inc | Healthcare | 1.16M | $98.81M | 2.16% | 0 | 0.0% | Unchanged | 0.83% |
| 14 | DYN Dyne Therapeutics, Inc. | Healthcare | 3.15M | $70.03M | 1.53% | 0 | 0.0% | Unchanged | 1.9% |
| 15 | ASND Ascendis Pharma A/S | Healthcare | 225.2K | $60.05M | 1.31% | +91.8K | +68.9% | Added | 0.37% |
Tip. Select a row to see that position’s full history at Frazier Life Sciences Management.
As of its Q2 2026 13F filing, Frazier Life Sciences Management, L.P.’s five largest positions were Mirum Pharmaceuticals, Inc. (MIRM) at 19.6%, NewAmsterdam Pharma Co N.V. (NAMS) at 13.4%, Erasca, Inc. (ERAS) at 10.0%, MBX Biosciences, Inc. (MBX) at 8.0%, Arcutis Biotherapeutics, Inc. (ARQT) at 5.7% of the reported portfolio.
Frazier Life Sciences Management, L.P. reported a 13F portfolio worth $4.58B across 40 positions for Q2 2026. That is up 21.3% from the previous quarter.
Its largest purchases by value were Parabilis Medicines, Inc. ($52.57M), Achieve Life Sciences, Inc. ($49.72M), NewAmsterdam Pharma Co N.V. ($38.81M). It opened 6 new positions.
Its largest sales by value were BridgeBio Pharma, Inc. ($141.51M), Revolution Medicines, Inc. ($65.71M), Agios Pharmaceuticals, Inc. ($42.49M). It exited 2 positions entirely.
From the Form 13F-HR reports Frazier Life Sciences Management, L.P. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.